To the Editor-Crawshaw et al 1 report a 4.5% and 6% 5-year progression rate to anal cancer in patients in the high-resolution anoscopy and "expectant management" arms and conclude that the method of following the patient is not important. We would argue that the reported incidence of cancer in both arms was too high, and we question whether the methods used by the authors to follow and treat patients in either arm were optimal. their rates are not much different from the estimates of progression among patients undergoing no therapy at all. 2 in contrast to the statement that "Anal intraepithelial neoplasia (AiN) rarely progresses to cancer," extended over an average lifetime, these rates would lead to a high lifetime risk of anal cancer and should not be considered acceptable.
the data in this article tell us little about how well a properly implemented prevention program might work. to achieve optimal results, high-resolution anoscopy should be performed by well-trained and experienced clinicians who have undergone rigorous evaluation and quality control, similar to that required for cervical colposcopy in cervical cancer prevention programs. Efforts must be to identify all high-grade squamous intraepithelial lesions (hsiLs); foci of hsiL that are not identified are also not targeted for ablation and can progress to cancer. the efficacy of hsiL treatment must be documented on posttreatment follow-up, because partially treated hsiL may progress to cancer. Patients must be followed regularly over a period of years because hsiL may require more than 1 treatment, and there is a high incidence of metachronous disease. data from a sufficient number of patients must be analyzed to permit scientifically meaningful conclusions. the article by Crawshaw et al falls short on all of these counts. A large, randomized controlled trial called the ANChor (ANal Cancer/hsiL outcomes research) study has just begun and is designed to definitively address this question by randomly assigning more than 5000 hiV-positive persons with hsiL to either treatment or close monitoring without treatment. Until the outcome of the ANChor study is known, we believe that it is a mistake to conclude that the methods used to diagnose and treat hsiL to prevent anal cancer do not matter. i have long argued that hrA and ablation should largely be carried out in office and not in an operating room, as performed at the authors' institution. i do not know any research studying imiquimod as an adjuvant post-hsiL ablation recommending it as the standard of care. Why is this done at the authors' institution with no data? the authors state that the cost and morbidity of hrA might not be warranted, but they have not looked at cost and morbidity in their own series. Last but not least, three end points in a grossly underpowered study do not make for strong conclusions, especially when 1 of the patients undergoing expectant management developed advanced anal cancer requiring salvage abdominoperineal resection.
research showed that most colon and rectal surgeons do not do hrA, and of those who do, most are untrained. 6, 7 isn't it time that we stopped trying to find excuses to not learn hrA and just take a course? it is, after all, about better patient care, and there are not sufficient data here to support expectant management as better patient care.
